August 1, 2019

Personalis, Inc. Announces Integration of New ImmunoID NeXT Platform™ Features in Latest Expansion of Immuno-Oncology Biomarker Discovery Applications

MENLO PARK, Calif.--(BUSINESS WIRE)--Aug. 1, 2019--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the latest expansion of its universal cancer immunogenomics platform, ImmunoID NeXT, incorporating several additional features that are pivotal to the understanding of tumor and immune cell interactions and how the nature of these interactions can impact cancer patients’ ability to respond to immunotherapies and combination therapies. These features include the analysis of human leukocyte antigen (HLA) loss of heterozygosity (LOH), the presence (or absence) of seven of the most common oncogenic viruses, as well as the composition of the T-cell receptor (TCR) alpha repertoire, which is complementary to the previously-released TCR beta analysis.

Through the deep interrogation and analysis of approximately 20,000 genes in both DNA and RNA, ImmunoID NeXT consolidates multiple biomarker assays into one, providing a multidimensional view of the tumor- and immune-related components of the tumor microenvironment from a single sample. The platform is an end-to-end solution for immuno- and precision oncology biomarker discovery applications, and in addition to these new features, it simultaneously enables the analysis of:

  • Tumor escape and primary/acquired drug resistance mechanisms
  • Adaptive immune cell receptor clonotypes and repertoire clonality
  • Innate immune cells
  • Predicted tumor-specific neoantigens
  • HLA typing and somatic mutations
  • Neoantigen load and tumor mutational burden (TMB)
  • Microsatellite instability (MSI) status
  • Somatic single nucleotide variations (SNVs), insertions/deletions (indels), gene fusions, and copy number alterations (CNAs)
  • Germline variants

Personalis CSO, Richard Chen, MD, said, “With the integration of these additional capabilities, we’re continuing to demonstrate our commitment to maximizing the biological insights that can be derived from single tumor samples, which are often limited in availability. While the roles of the adaptive immune cells and oncoviruses are well documented in many cancer types, HLA LOH has emerged as an important, potential resistance mechanism to immunotherapy. We’re excited to be one of the first commercial providers of this analysis as part of ImmunoID NeXT™, the premier tumor immunogenomics platform for comprehensive biomarker evaluation in both solid and hematologic cancer indications.”

About Personalis, Inc.

Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The company’s NeXT™ Platform is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. The Personalis Clinical Laboratory is GxP aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit and follow Personalis on Twitter (@PersonalisInc).

Source: Personalis, Inc.

Investor Relations Contact for Personalis:
Caroline Corner

Media Contact for Personalis:
Jennifer Havlek